HSBC Raises Biogen Price Target to $150

Analysts see potential downside of 18.6% from previous close.

Mar. 17, 2026 at 1:42pm

Got story updates? Submit your updates here. ›

Research analysts at HSBC have raised their price target for Biogen (NASDAQ:BIIB) stock from $143 to $150, suggesting a potential downside of 18.6% from the stock's previous close. Several other equity analysts have also recently commented on Biogen, with ratings ranging from 'neutral' to 'outperform' and price targets between $185 and $236.

Why it matters

Biogen is a major biotechnology company focused on developing treatments for neurological and neurodegenerative diseases. Analysts' price targets and ratings can significantly impact investor sentiment and trading activity around the stock.

The details

HSBC's new $150 price target for Biogen represents a potential downside of 18.6% from the stock's previous close. Other analysts have also weighed in, with UBS Group assuming coverage and assigning a 'neutral' rating and $185 price target, while Mizuho increased their price target from $207 to $236 and maintained an 'outperform' rating. Overall, the consensus rating on Biogen is 'Hold' with an average price target of $205.31.

  • The new HSBC price target was issued on Tuesday, March 17, 2026.

The players

Biogen

A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases, headquartered in Cambridge, Massachusetts.

HSBC

A global financial services company that provided the new $150 price target for Biogen stock.

UBS Group

A global financial services firm that assumed coverage of Biogen stock with a 'neutral' rating and $185 price target.

Mizuho

A Japanese financial services group that increased its Biogen price target from $207 to $236 and maintained an 'outperform' rating.

Got photos? Submit your photos here. ›

The takeaway

Biogen's stock price continues to be closely watched by analysts, with a range of price targets and ratings reflecting the company's importance in the biotechnology sector and its potential to develop new treatments for neurological diseases.